IRESSA*
- Gefitinib - @ - Epidermal Growth Factor Receptor Inhibitors - Antineoplastic Agents- (Feb 2004)
Compositions:
Gefitinib- mg,  
List of Related Indications:
Gefitinib- mg,
- For the treatment of Patients with metastatic Non-Small Cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutation as detected by an FDA -approved test
| Strength | Rate | Packing Style | 
|---|---|---|
| mg | 0.00 | unit | 

 
   
                             
                             
                             
                             
                             
                             
                             
                             
                             
                         Manufacturer Details
Manufacturer Details